JP2023510349A5 - - Google Patents

Info

Publication number
JP2023510349A5
JP2023510349A5 JP2022542333A JP2022542333A JP2023510349A5 JP 2023510349 A5 JP2023510349 A5 JP 2023510349A5 JP 2022542333 A JP2022542333 A JP 2022542333A JP 2022542333 A JP2022542333 A JP 2022542333A JP 2023510349 A5 JP2023510349 A5 JP 2023510349A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
conjugate
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510349A (ja
JP7846624B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012611 external-priority patent/WO2021142199A1/en
Publication of JP2023510349A publication Critical patent/JP2023510349A/ja
Publication of JP2023510349A5 publication Critical patent/JP2023510349A5/ja
Priority to JP2026061557A priority Critical patent/JP2026117046A/ja
Application granted granted Critical
Publication of JP7846624B2 publication Critical patent/JP7846624B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542333A 2020-01-09 2021-01-08 ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート Active JP7846624B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026061557A JP2026117046A (ja) 2020-01-09 2026-04-03 ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062958916P 2020-01-09 2020-01-09
US62/958,916 2020-01-09
US202063040735P 2020-06-18 2020-06-18
US63/040,735 2020-06-18
PCT/US2021/012611 WO2021142199A1 (en) 2020-01-09 2021-01-08 Site specific antibody-drug conjugates with peptide-containing linkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026061557A Division JP2026117046A (ja) 2020-01-09 2026-04-03 ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2023510349A JP2023510349A (ja) 2023-03-13
JP2023510349A5 true JP2023510349A5 (cg-RX-API-DMAC7.html) 2024-01-19
JP7846624B2 JP7846624B2 (ja) 2026-04-15

Family

ID=74495099

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022542333A Active JP7846624B2 (ja) 2020-01-09 2021-01-08 ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート
JP2026061557A Pending JP2026117046A (ja) 2020-01-09 2026-04-03 ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026061557A Pending JP2026117046A (ja) 2020-01-09 2026-04-03 ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート

Country Status (12)

Country Link
US (2) US11786605B2 (cg-RX-API-DMAC7.html)
EP (1) EP4087614A1 (cg-RX-API-DMAC7.html)
JP (2) JP7846624B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220124762A (cg-RX-API-DMAC7.html)
CN (1) CN115884793A (cg-RX-API-DMAC7.html)
AU (1) AU2021205312A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022013255A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163833A1 (cg-RX-API-DMAC7.html)
IL (2) IL326905A (cg-RX-API-DMAC7.html)
MX (1) MX2022008437A (cg-RX-API-DMAC7.html)
TW (1) TW202140075A (cg-RX-API-DMAC7.html)
WO (1) WO2021142199A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022013255A2 (pt) 2020-01-09 2022-09-06 Mersana Therapeutics Inc Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
WO2022147532A1 (en) 2021-01-04 2022-07-07 Mersana Therapeutics, Inc. B7h4-targeted antibody-drug conjugates and methods of use thereof
WO2023141856A1 (zh) * 2022-01-27 2023-08-03 岩唐生物科技(杭州)有限责任公司 靶向cd3的多特异性抗体及其应用
KR20250089528A (ko) * 2022-10-18 2025-06-18 투불리스 게엠베하 신규한 napi2b 항체를 함유하는 신규한 항체 약물 접합체, 치료 방법 및 이의 용도
WO2025248500A1 (en) 2024-05-31 2025-12-04 Janssen Biotech, Inc. Antibody drug conjugates that target enpp3
WO2026017107A1 (en) * 2024-07-19 2026-01-22 Primelink Biotherapeutics (Shenzhen) Co., Ltd. Linker-polymer-drug conjugates

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
AU2004204463B2 (en) 2003-01-10 2009-02-12 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Catalytic domains of beta(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US7807619B2 (en) 2004-11-01 2010-10-05 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US8367065B2 (en) 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2250201B1 (en) 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
WO2009102820A2 (en) 2008-02-11 2009-08-20 Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services Modified sugar substrates and methods of use
US8859629B2 (en) 2010-04-27 2014-10-14 Synaffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
GB201115841D0 (en) 2011-09-13 2011-10-26 Genovis Ab Protein and method
US9199237B2 (en) * 2012-09-04 2015-12-01 Michael Baumgartner Automated well plate
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
EP3004062B1 (en) 2013-05-24 2017-07-19 SynAffix B.V. Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
WO2015057065A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
CA2943984A1 (en) * 2014-06-12 2015-12-17 Halliburton Energy Services, Inc. Determination of substance presence, identity and/or level in vessels
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗her2表位之單株抗體及其使用之方法
EP3177633B1 (en) 2014-08-04 2022-07-20 SynAffix B.V. Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
CN107810273B (zh) 2015-04-23 2022-09-27 西纳福克斯股份有限公司 用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
EP3414328B1 (en) 2016-02-08 2024-01-10 Synaffix B.V. Enzymes for trimming of glycoproteins
WO2017137457A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
WO2017137458A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
US20180098269A1 (en) * 2016-04-25 2018-04-05 Telefonaktiebolaget Lm Ericsson (Publ) System Information Configuration Update in a Wireless Communication Network
US11135307B2 (en) * 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體-藥物結合物之組合療法
EP3685166A2 (en) 2017-09-20 2020-07-29 Mersana Therapeutics, Inc. Compositions and methods for predicting response to napi2b-targeted therapy
BR112022013255A2 (pt) 2020-01-09 2022-09-06 Mersana Therapeutics Inc Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
WO2022147532A1 (en) * 2021-01-04 2022-07-07 Mersana Therapeutics, Inc. B7h4-targeted antibody-drug conjugates and methods of use thereof

Similar Documents

Publication Publication Date Title
TWI847992B (zh) 抗體-藥物結合物之有效的製造方法
JP2022095908A5 (cg-RX-API-DMAC7.html)
US20260139074A1 (en) Combination of antibody-drug conjugate and tubulin inhibitor
IL302078A (en) Anti-CCR8 monoclonal antibodies and their uses
JP2024501894A5 (cg-RX-API-DMAC7.html)
JP2020509027A5 (cg-RX-API-DMAC7.html)
JP2023539715A5 (cg-RX-API-DMAC7.html)
JPWO2021177438A5 (cg-RX-API-DMAC7.html)
JP2022519273A5 (cg-RX-API-DMAC7.html)
JP2023545096A5 (cg-RX-API-DMAC7.html)
EP3804764A1 (en) Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
JP2023548051A5 (cg-RX-API-DMAC7.html)
US20260115306A1 (en) Combination of anti-cdh6 antibody-drug conjugate and vegf inhibitor
CN114450025A (zh) 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症
JP2025517908A5 (cg-RX-API-DMAC7.html)
US20260021194A1 (en) Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
JP2024536383A5 (cg-RX-API-DMAC7.html)
CN112996540A (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
AU2024316626A1 (en) Anti-ror1 protein antibody and conjugate thereof
JP2020507569A5 (cg-RX-API-DMAC7.html)
JPWO2022019259A5 (cg-RX-API-DMAC7.html)
IL300030A (en) Combination of an anti-2HER drug-antibody conjugate with a dimerization suppressor
WO2026098619A1 (zh) 一种egfr×her3双特异性抗体药物偶联物、其制备方法和应用
WO2025164597A1 (ja) 抗her2抗体-薬物コンジュゲートと他剤との組み合わせ
TW202535465A (zh) 抗cd147抗體與其他抗腫瘤劑之組合